Industries > Pharma > Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029

Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029

CTLA-4 Inhibitors, PD-1 Inhibitors, 3 PD-L1 Inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Pipeline Drugs

PUBLISHED: 28 May 2019
PAGES: 152
PRODUCT CODE: PHA0423

Clear
WOOCS 2.2.1

The global checkpoint inhibitors for anti-cancer treatment market is estimated to have reached $11.43 bn in 2018 and is expected to grow at a CAGR of 13.7% during the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 152-page report you will receive 72 tables and 32 figures– all unavailable elsewhere.

The 152-page report provides clear detailed insight into the global checkpoint inhibitors for anti-cancer treatment market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029

• Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Leading Drugs:
• Yervoy (ipilimumab)
• Opdivo (nivolumab)
• Keytruda (pembrolizumab)

• Global Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by Class:
• CTLA-4 Inhibitors
• PD-1 Inhibitors
• Pipeline Drugs

• Checkpoint Inhibitors Anti-Cancer Treatment Market forecasts from 2018-2029 by regional and national market:
• U.S.
• EU: Germany, France, Italy, U.K., Spain
• Japan
• APAC

Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029

• Profiles of the selected leading companies:
• AstraZeneca, Plc
• Bristol-Myers Squibb Co.
• Celldex Therapeutics, Inc.
• Incyte Corporation
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Roche Holding AG

• The Checkpoint Inhibitors Anti-Cancer Treatment Market Pipeline Analysis

• A SWOT analysis of the global checkpoint inhibitors anti-cancer treatment market

• Key Questions Answered by this Report:
• What are the global revenue prospects for the period 2018 to 2029?
• What are the leading national market potentials from 2018 to 2029?
• How is the checkpoint inhibitor anti-cancer treatment drugs market evolving?
• What is driving and restraining the checkpoint inhibitor anti-cancer treatment drugs market?
• What are the market shares of each segment of the overall checkpoint inhibitor anti-cancer treatment drugs market?
• How will main checkpoint inhibitor anti-cancer treatment submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029?
• Which therapies can succeed and what revenues could they generate to 2029?
• What will be the main commercial drivers for the market from 2018 to 2029?
• How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
• How will that industry evolve between 2018 and 2029, especially in R&D?

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Checkpoint Inhibitors Anti-Cancer Treatment Drugs Market. You find data, trends and predictions.

Buy our report today Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029: CTLA-4 Inhibitors, PD-1 Inhibitors, 3 PD-L1 Inhibitors, Ipilimumab, Nivolumab, Pembrolizumab, Pipeline Drugs.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Checkpoint Inhibitors for Anti-Cancer Treatment Market 2019-2029


Latest Pharma news

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

READ

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

READ

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

READ

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

READ

Categories

Category